Leukemia is a disease that develops as a result of changes in the genomes of hematopoietic cells, a fact first appreciated by microscopic examination of the bone marrow cell chromosomes of affected patients. These studies revealed that specific subtypes of leukemia diagnoses correlated with specific chromosomal abnormalities, such as the t(15;17) of acute promyelocytic leukemia and the t(9;22) of chronic myeloid leukemia. Over time, our genomic characterization of hematologic malignancies has moved beyond the resolution of the microscope to that of individual nucleotides in the analysis of whole-genome sequencing (WGS) data using state-of-the-art massively parallel sequencing (MPS) instruments and algorithmic analyses of the resulting data. In addition to studying the genomic sequence alterations that occur in patients' genomes, these same instruments can decode the methylation landscape of the leukemia genome and the resulting RNA expression landscape of the leukemia transcriptome. Broad correlative analyses can then integrate these 3 data types to better inform researchers and clinicians about the biology of individual acute myeloid leukemia (AML) cases, facilitating improvements in care and prognosis. Semin Hematol 51:250-258. C 2014 Elsevier Inc. All rights reserved.
L eukemia is a disease that develops as a result of changes in the genomes of hematopoietic cells, a fact first appreciated by microscopic examination of the bone marrow cell chromosomes of affected patients. These studies revealed that specific subtypes of leukemia diagnoses correlated with specific chromosomal abnormalities, such as the t(15;17) of acute promyelocytic leukemia 1 and the t(9;22) of chronic myeloid leukemia. 2 Over time, our genomic characterization of hematologic malignancies has moved beyond the resolution of the microscope to that of individual nucleotides in the analysis of whole-genome sequencing (WGS) data using state-of-the-art massively parallel sequencing (MPS) instruments and algorithmic analyses of the resulting data. In addition to studying the genomic sequence alterations that occur in patients' genomes, these same instruments can decode the methylation landscape of the leukemia genome and the resulting RNA expression landscape of the leukemia transcriptome. Broad correlative analyses can then integrate these 3 data types to better inform researchers and clinicians about the biology of individual acute myeloid leukemia (AML) cases, facilitating improvements in care and prognosis.
Historically, DNA sequencing by using the Sanger dideoxynucleotide method 3 required 2 decoupled steps: (1) the DNA polymerase-catalyzed sequencing reaction during which fluorescent labels are incorporated into the ladder of synthesized strands; and (2) the electrophoretic separation and detection of the fluorescently labeled sequencing reaction fragments. Although this method was used successfully for small and large sequencing projects, including sequencing the human reference genome, 4 the introduction of massively parallel, or "next-generation" sequencing (NGS), platforms over the past decade has radically changed the nature of DNA sequencing. 5, 6 There are fundamental differences in this type of sequencing that inherently enable massive data generation in a truncated time frame, at significantly lower cost than with the use of the Sanger-based methods. In particular, a next-generation platform sequencing library requires only a few discrete molecular biology reactions to generate, starting from either fragmented high molecular weight genomic DNA, complementary DNA (RNA converted to DNA by reverse transcriptase), or polymerase chain reaction (PCR) products.
After library generation, the fragments are polymerase amplified on a solid surface, either a nonporous bead or flat microfluidic channel. The amplification of discrete fragments enables the signals generated during the sequencing reaction to have sufficient intensity for detection. Data generation takes place after priming of all DNA fragments in the amplified population, using a step-wise process to extend from each primer end with an incorporated nucleotide, remove the excess nucleotides, and detect the identity of that incorporated nucleotide at each fragment location. The en masse data generation mode enabled by these methods invokes the term "massively parallel," and the generated data volumes can be sufficient to produce coverage of a complete human genome. Unlike Sanger sequencing, which produces data from a population of fragments for each reaction, massively parallel platforms generate data from individually amplified library fragments. As a result, the data are digital, maintaining a 1:1 relationship in terms of the fragment population to the copy number present in the input DNA source. Downstream analyses can invoke this digital nature in exact quantitation of DNA copy number, RNA expression, the proportions of mutation-containing cells in a population, and other characterizations.
During the multiple rounds of sequence data generation steps, various sources of noise emerge, ultimately limiting the read length that can be obtained at the point that signal and noise are not well differentiated and the quality of the called nucleotide is questionable. As manufacturers of these platforms have improved their chemistry, molecular biology, and imaging sensitivity and decreased their cycle times, the read lengths have improved. At present, however, read lengths are significantly shorter than from Sanger-based sequencing data, making read alignment to a reference genome necessary for interpretation of the resulting data. However, the improving quality of the human reference genome and of algorithms that accurately place sequencing reads from a massively parallel experiment onto the genome sequence fueled a revolution in our ability to characterize genomes at many levels, as will be described.
In the sequencing of cancer-derived DNA, the typical goal is to determine changes that are unique to the tumor genome or are "somatic." Here, the scope and digital nature of MPS enables a vast number of somatic variant discoveries when comparing data from tumor versus matched normal tissue isolates from patient samples. The following sections explore this comparison across the spectrum from whole genome to exome to gene panel sequencing assays. In addition to surveying the tumor-specific alterations of DNA, the RNA landscape and the methylation landscape can also be studied. RNA and methylation patterns are perhaps most informative when compared with a matched normal tissue from the same patient. However, a comparator or matched normal tissue is often not possible to obtain or the cell type is not identified or known; interpretation may therefore be limited to comparing results either with large numbers of surveyed normal tissues or with reference datasets, when they exist.
CHALLENGES OF NGS USING CLINICAL AML SAMPLES
In general, the challenges of next-generation assays to characterize DNA derived from bone marrow or blood cells are unique to the hematologic malignancies and are different from those of solid tissue malignancies. For example, bone marrow samples often provide abundant tumor DNA/RNA sources for assay, with low amounts of contaminating normal cells. By contrast, some tissues (eg, myeloid sarcomas) will require flow sorting to enrich the tumor cell population before nucleic acid isolation, a process that often produces a limited number of cells and hence a limited source of nucleic acid for the NGS assays. Another challenge is due to the comparator normal tissue, often obtained from skin taken at the marrow biopsy site. In many cases, skin biopsy specimens from AML patients with high circulating white cell counts (or leukemias with monocytic differentiation) will present a contaminating source of tumor nucleic acids, due to the capillary beds present in skin. Furthermore, limited amounts of skin are available for nucleic acid isolation, and substituting buccal swabs or mouthwash samples contributes a microbiome component to the DNA/RNA isolation that will make the sequencing less efficient in terms of obtaining coverage on the human genome. As mentioned earlier, for RNA and methylation analyses, a true comparator normal tissue may either not be known or is controversial. In this case, comparisons of expression or methylation signatures across multiple affected tissues are required to build a case that any given expressed gene(s) or methylation change is contributing to disease onset or progression. Figure 1A outlines a process for WGS data generation that is applicable to generate the coverage needed from an MPS platform. WGS is widely considered to be the gold standard for cancer sequencing because it provides data that can be interpreted across the broad spectrum of somatic variation, from single nucleotide substitution mutations to large structural rearrangements. All of these types of variants have been demonstrated to create "drivers" of cancer development, and hence a WGS approach will provide the most complete information about somatic alterations, but these are also the most expensive and most difficult data to analyze. 7 There are multiple considerations when planning a WGS study to compare matched tumor and normal genomes; these considerations include having a fundamental understanding of the following: (1) the purity of tumor cells being used for the sequencing library; (2) the relative amount of chromosomal amplification or loss present in the tumor genome; and (3) the types of variants that one wants to detect from the resulting data. All 3 factors contribute to the amount of genome "coverage" to be generated, in which coverage is defined as the depth of whole-genome sampling required to discover variants. In particular, if the tumor purity is o100%, additional coverage will be required to compensate for the normal cell A detailed series of steps is followed to make a massively parallel sequencing library, beginning with a genomic DNA sample. High molecular weight DNA extracted from human tissues can be fragmented by sonication using high-frequency sound waves. After the fragmentation, the ends are repaired to blunt them by using a combined enzymatic fill-in and removal of overhanging ends. The blunted ends are phosphorylated, enabling the addition of adenosine at the ends, and providing a hybridization and ligation point for sequencing platform-specific adapters. The adapters are synthetic DNAs that correspond to covalently linked adapters on the support surface used for an enzymatic amplification step before sequencing. Several library construction steps, marked by blue stars, require polymerase chain reaction to amplify the products before the next process step, which can introduce bias in representation of the library content. QC, quality control.
WHOLE-GENOME SEQUENCING
genome contributions to the library. If there are large-scale chromosomal arm or whole chromosome amplifications, additional sequencing coverage will be needed to bring diploid regions of the genome up to sufficient coverage levels to detect variants. Typically, ploidy is gauged either by using signal strength-based analysis of the tumor DNA after hybridization to a high-density single nucleotide polymorphism (SNP) microarray platform or by cytogenetic examination of the tumor chromosomes.
Because most tumor WGS projects seek to identify single nucleotide substitution and focused insertion/deletion mutations, a minimum coverage of 30-fold for the tumor genome (with caveats listed earlier) is required. Although copy number and structural variant alterations can be detected from 30-fold coverage, the false-positive rate (FPR) of discovery and the false-negative rate of missed events of these types both decrease with increasing coverage. Routinely, tumor DNA WGS libraries are sequenced at 50-to 60-fold coverage to enhance discovery of more complex alterations, and the confidence of mutation detection increases commensurately. Lower tumor purity can be compensated for by increasing coverage, as can chromosomal ploidy differences. In particular, one helpful gauge of achieving appropriate coverage for mutation detection is by comparing the variants identified by using massively parallel data (aligned to the genome and with variants identified genome-wide) versus the SNP calls at these loci as obtained from the array data proposed earlier to gauge chromosomal amplification. In particular, as one approaches 98% concordance between SNP array calls and single nucleotide variant calls from MPS data, sufficient coverage for mutation detection can be assured.
Library construction for optimal WGS coverage requires an approach that fulfills the following criteria: (1) sufficient diversity in the library fragment population to obtain the desired coverage without exhausting uniqueness; (2) input DNA quantities sufficient to provide the desired coverage without exhausting uniqueness; and (3) tight size fractions that enable structural variant detection with precision and low FPR. In situations with low input and/or fragmented DNA (eg, from formalinpreserved tissue isolates), a method to provide library fragment diversity and minimize duplication rates must be used.
The primary challenge to maintaining a diverse fragment population during library construction is due to the use of PCR at various steps, as illustrated in Figure 1B . In particular, PCR can introduce amplification biases (often referred to as "jackpotting") that result in certain fragments being preferentially amplified and not others. This preferential amplification is often a function of A þ T content and of DNA fragment size. Furthermore, if a limited amount of DNA (o50 ng) is used for library construction, the low input portends a relative lack of diversity that is exacerbated by PCR amplification steps. In general, limited material is common in clinical samples; thus, at the Washington University Genome Institute, we have carefully titrated the input amounts of several components in library construction such as the synthetic adapters, reduced the number of DNA loss steps by using a universal buffer for several of the enzymatic treatments, and established a process for "titrating" to find the minimum number of PCR amplification cycles before a high degree of amplification bias develops. 8 For WGS projects, we also commonly select 2 to 4 size ranges during the final library preparatory steps, either by polyacrylamide gel sizing and excision relative to a co-electrophoresed size standard or by using an automated sizing device such as the Caliper LabChip XT (PerkinElmer Inc., Waltham, Massachusetts) or the BluePippin (Sage Science, Inc., Beverly, Massachusetts). These approaches can isolate discrete size fractions of Ϯ50 bp that are amenable to somatic structural variant detection algorithms (ie, BreakDancer 9 ). In sequencing these different size fractions, we produce equal amounts of data from 2 to 4 of the collected fractions to ensure library fragment diversity and hence complete genome coverage.
Once genome coverage is accumulated to the desired depth for both tumor and normal WGS, aligned to the human reference genome, and checked for satisfactory correlation to array-called SNPs, the analytical process to compare tumor versus normal can begin. A thorough review of somatic variant detection algorithms and pipelines is not the focus of the present review; it is worth noting, however, that there is no perfect algorithm for any given type of somatic variant detection. In particular, because of the situation discussed earlier, when tumor cells are present in the skin biopsy specimen used for the comparator normal genome, somatic variant detection in hematopoietic malignancies poses unique challenges. Due to the large numbers of algorithms available to identify point mutations, focused insertion/deletions, and structural/copy number variants, a common approach is to identify the top 2 to 3 algorithms for each variant class (often these will use different algorithms to identify variants) and to combine their output at the first pass to ensure comprehensive discovery. Because this approach also assures a significant false-positive rate, using a secondary validation step to cull false-positive findings is necessary. We have found the best approach to wholegenome variant validation is to have a custom set of capture probes synthesized for each genome set of variant sites, enabling hybrid capture from the whole-genome libraries of tumor and normal so these sites can be sequenced, aligned, and analyzed a second time. The following sections outline the hybrid capture approach and its fundamentals.
A secondary advantage of generating data from specific capture probes is the high coverage depth that results at the subsequently validated variant sites in the genome. In particular, our group 10,11 and others [12] [13] [14] have developed statistical approaches to estimating the genomic heterogeneity in a tumor sample based on sites of high coverage depth. Because the majority of these sites are heterozygous, the read population will consist of reads carrying either the wild-type or mutant allele. Because each read originates from one fragment in the library, the one-to-one relationship predicts that the number of variant-carrying reads correlates to the variant allele fraction (VAF) in the tumor cell population. By this logic, the oldest variants in the population should be present in every cell and hence should represent 50% VAF. Newer variants are present in fewer cells as calculated according to their VAF. In each case, VAF must be adjusted for tumor cell content of the sequenced cells and for variants that are found in copy number-altered regions of the genome. A secondary clustering method is then used to examine the VAF calculated for all variants and predict the founder clone (50% VAF) and the additional subclones present by virtue of shared VAFs.
EXOME SEQUENCING BY HYBRID CAPTURE
Although WGS offers a comprehensive ability to discover a broad range of variant types, it is an expensive option and is certainly the most difficult approach from an analytical sense, primarily due to the size and complexity of the human genome. Although this method was initially the only option for human genome sequencing, in 2008, several publications described the concept of "exome" sequencing, 15, 16 in which the exome is defined as the 1.5% of the human genome that contains annotated genes. These methods essentially involve solution-phase hybridization between biotinylated synthetic DNA or RNA probes that correspond to specific exon sequences from the genome and the whole-genome library fragments discussed earlier. By virtue of sequence similarity, these library fragments that contained exons or portions of exons would hybridize the sequence-specific probes in solution. Upon completion of the hybridization step, the libraryprobe hybrids were selectively precipitated from solution by the addition of streptavidin-coated magnetic beads that bound the biotin conjugates on the probes, and were then pulled to the reaction tube bottom by the application of a magnet. Reversing the hybridization by addition of heat permitted the release of the captured fragments into solution. These selected library fragments could then be amplified by PCR, quantitated, and sequenced. Although the resulting sequencing data are aligned to the human reference genome as the first step in analysis, the focused areas for variant discovery are specified by the territory these probes are designed to capture (defined by a BED format file). As such, the process of identifying exonic variants is more rapid, although fewer types of variants can be identified. Multiple commercial vendors of exome capture reagents are available that may offer significant additional coverage of regions around the exons of known genes, as well as including 5' and 3' untranslated regions, some known noncoding RNAs, and known promoter regions. A typical exome capture experiment aims for 100-fold coverage depth on average, although coverage at any given locus can vary substantially from that average. Typically, exons with high G þ C or A þ T content are not captured adequately, and there can be overall variability from one hybrid capture to another, leading to false-negative findings when either tumor or normal samples or both are not adequately covered to enable detection of variant bases.
Due to its low cost and ease of analysis compared with WGS, exome sequencing to compare tumor and normal samples has been conducted extensively across many tumor types. However, structural variants are not detected by using this method as a general rule, and copy number analysis is inherently difficult because differential probe performance in hybridization can masquerade as reporting copy number differences. When a commercial exome probe set is used, the cost to produce exome capture data is approximately one tenth that of the WGS process. This low cost reflects increases in per-run sequencing throughput, permitting libraries that carry a DNA barcode identifier to be pooled in an equimolar pool of 4 to 8 libraries, hybridized to the capture probe set, and then sequenced together. Once sequencing is completed, specific software uses the information from the DNA barcode to separate reads that originated from different libraries into "bins." Each bin of reads is then aligned to the human reference genome, permitting each sample to be evaluated individually for variants.
As discussed for WGS, the depth of exome sequencing data can be exploited to calculate VAFs, and these values subsequently can be clustered to estimate genomic heterogeneity in the sample, in which higher depth will provide more confident VAF calculation. This can be limited in tumor types such as AML, which have very low numbers of mutations in genes, 17 because there are insufficient numbers of variants to generate confident clustering. Sequencing depth can be important for other reasons, especially as it relates to the capability to detect pathogenic mutations that may be present in only a small proportion of cells and might indicate an "Achilles' heel" that could prove responsive to Z1 targeted therapy; it may also predict the tumor's capability to acquire resistance if a specific therapy is applied. As these types of mutations are better characterized, a set of probes can be included to enhance coverage at these sites that will maximize detection sensitivity. In addition, for areas in which commercial exome kits are known to routinely underperform in capture, or in which a novel, nonexonic region merits variant detection, additional synthetic probes corresponding to these regions can be synthesized and "spiked" into the exome capture reagent to provide sequencing read coverage.
TARGETED SEQUENCING BY HYBRID CAPTURE OR MULTIPLEX PCR
Even exome sequencing can provide a large amount of data for analysis, and often the exact genes that one wishes to target are known; hence, hybrid capture can be used with a defined probe set. Typically, this is referred to as a targeted "panel" of genes and follows the same basic steps as exome capture. Probes can be designed with the help of a commercial manufacturer who can synthesize and biotinylate them, providing the resulting probes as an equimolar mixture or as individual probes to mix and match. Alternatively, capture probes can be produced by first designing PCR primers to amplify the regions of interest and then biotinylating the PCR products by supplying biotinylated nucleotides into the PCR. 18 There is a lower limit to targeted capture; typically, 200 kb of target space is minimally efficient. Lower than this level, the yield of sequenced regions of interest relative to offtarget reads becomes very low, and the efficiency of sequencing is compromised.
However, smaller gene numbers or only sequencing specific mutational "hotspots" are often desired, and another approach can be used at this sub-200 kb sequencing scale. This approach, called multiplex PCR, attempts to design specific amplification primers for each site of interest such that the primers have approximately matched median annealing temperatures but do not have sequence similarity across the primer set. In a multiplex PCR, all primers are combined with the genomic DNA of interest into a PCR, and amplification occurs en masse by temperature cycling. At the completion of multiplex PCR, the resulting fragments are made into a library and sequenced by MPS. Subsequent alignment and variant analysis are as described for exome capture. There are several challenges in multiplex PCR, including: (1) the need to optimize primer pairs so that amplification is as robust as possible at all sites and primer-primer interactions are minimized; and (2) the need to design amplicons of approximately the same size range, thereby minimizing biases in amplification and maximizing sequencing coverage across the length of each product. The first challenge is made difficult when one wishes to study gene families or if exons across certain genes have high G þ C or A þ T content. The second challenge requires a relatively uniform PCR product size as determined by the sequencing read length, such that genes with long exons will have multiple PCR products to represent the entire exon sequence. Another challenge is in the detection of PCR biasing (jackpotting), discussed earlier. Essentially, it is impossible to use conventional NGS deduplication algorithms to detect and remove duplicates of PCR products because they begin and end at the same sequences by definition (those provided by the primer pairs themselves). Hence, a secondary orthogonal validation scheme is necessary, especially if high-depth coverage is planned. As these challenges are realized, often what results will be multiple PCR primer sets that each have specific annealing and extension temperatures optimized for the loci being targeted. Before sequencing, the resulting PCR products are pooled to produce a broader target region of data than possible from a single multiplex reaction.
TRANSCRIPTOME SEQUENCING
As interest in RNA assays increases, due to the realization that sequencing RNA from tumors provides a broad variety of data germane to our understanding of cancer biology, many attendant challenges of "RNA-seq" will be identified. RNA is transcribed from the genome across a broad range of sizes and although not all functions are known for all RNAs produced in the cell, there are emerging lines of evidence that noncoding RNAs of several classes are integral to cancer biology. [19] [20] [21] [22] [23] Furthermore, RNA-based discovery includes cataloguing of expression levels, alternative splicing, mutation expression, and fusion detection, and hence depends on the use of many different algorithms. As such, an RNA-seq analytical pipeline can be lengthy and complicated to assemble and to validate.
RNA is a labile molecule; therefore, obtaining highquality RNA from clinical samples can often be difficult, especially due to the common pathology practice of formalin fixation and paraffin embedding wherein formalin crosslinks chemically with the nucleic acid backbone, resulting in strand breaks and hence degradation. Similarly, paraffin at temperatures Z65 o F will degrade RNA by hydrolysis during the embedding process.
Another difficult aspect of RNA sequencing from clinical samples is that limited quantities are typical, especially when derived from samples with low tumor content, because laser capture microdissection or flow sorting must be used to enhance the tumor cell content into the isolation. Unlike DNA, increasing coverage on RNA sequencing data cannot compensate for low tumor cell content from a bulk isolate; therefore, tumor cell enrichment steps must be performed before RNA isolation.
However, RNA amplification is straightforward and has high fidelity to the original expression levels of genes in the tissue; input as low as 50 pg of total RNA can therefore result in a workable yield of amplified total RNA. If poly(A) selection is desired as a means to solely focus sequencing on gene-encoding RNAs, the use of low-input samples is obviated. Namely, poly(A)þ RNA constitutes 2% of the total RNA population; hence, isolation of poly(A)þ RNA from low-input samples will not yield a workable RNA amount for downstream library construction and sequencing.
Recently, we demonstrated that very low amounts (50 pg) of total RNA from fresh frozen or formalin-fixed paraffin-embedded tissue can be sequenced to obtain improved on-gene coverage by use of an intermediate hybrid capture step that precedes sequencing. 24 Such an approach can also be used in cases in which a fusion gene transcript is suspect or for diagnostic purposes (ie, known fusion drivers in hematologic malignancies such as PMLRARa, BCR-ABL). In these cases, including probes into the hybrid capture reagent that tile along the exons of the fusion transcript loci, coupled with focused analysis to identify the fusions captured, will yield fusion transcripts if present. Several groups now are exploring single-cell RNA sequencing to examine the intercell differences in gene expression between cells from the same tissue. 25, 26 Careful analyses of these data to exclude results that are stochastic noise are required for single-cell experiments. 27 As with DNA sequencing, the analysis of RNA-seq data starts with alignment to the human reference genome but requires specific algorithms for this purpose, and these may be fine-tuned further to permit specific types of RNA-based discovery. 28, 29 For example, although detection of alternative splicing or of fusion transcripts is relatively difficult, it is aided by specific algorithms that identify split read alignments, effectively permitting the sequencing read to be split across a gene or genomic segment. 30 Studying RNA by sequencing is informative for many reasons. First, overexpression of specific RNAs may be detected in tumors that are absent correlative signals in the DNA (eg, as a regional amplification). Because overexpressed genes can be drivers of cancer development (eg, human epidermal growth factor receptor 2/neu, epidermal growth factor receptor), it is critical to collect these data because overexpression is not always simply a consequence of chromosomal amplification. Second, studying the expression of mutated genes identified from DNA analysis in the RNA-seq data can be informative in terms of which mutated genes are also expressed in the tumor cells. On average, approximately one half of the genes mutated in a cancer genome are not expressed in the corresponding RNA population, either by selective silencing of the mutated allele or due to lack of gene expression in its entirety. Third, although detecting structural variations in DNA has a high FPR, the combined evidence from DNA (by end-read mapping) coupled with RNA fusion detection (from NGS) can confirm predicted fusions. [31] [32] [33] Ultimately, as transcription factor and enhancer/repressor binding sites in the genome are better characterized, mutations in these regions may be correlated to RNA expression for the affected genes, representing yet another type of correlative analysis. 34 Taken together, the integration of DNA and RNA sequencing data is providing very powerful insights into tumor biology.
METHYLOME AND EPIGENOME SEQUENCING
Another type of DNA-based characterization that is becoming increasingly common is whole-genome or targeted methylation sequencing ("methyl-seq"). [35] [36] [37] [38] The addition of methyl groups to DNA is one regulatory mechanism used by the cell's transcription machinery to indicate which genes are silenced and which are active. Unmethylated cytosines can be readily converted by treatment of the DNA with sodium bisulfite, 39 providing a strategy to quantify methylated versus unmethylated cytosine residues. These studies provide an integral dataset with which to characterize cancer genomes. There are nuances to the types of cytosine methylation found on DNA, including differential methylation with 5-hydroxymethyl groups, formyl methyl groups, and perhaps others yet to be described. Efforts to chemically mark these different types of methyl groups, followed by sequencing, are being developed as commercial kits. 40, 41 The major challenges in methylation sequencing are 2-fold: (1) the ideal depth of coverage remains somewhat elusive in terms of single-CpG resolution, 42 especially for detecting minor methylation marks such as 5-hydroxymethyl C residues; and (2) bioinformatic analysis of the resulting data to identify unmethylated and methylated nucleotides remains challenging in the context of a high FPR/falsenegative rate (in which the latter is due to suboptimal coverage). One approach to address the cost of generating higher coverage is to down-sample the methylated genome by virtue of reduced representation bisulfite sequencing. 43, 44 More recently, commercial vendors have produced probes for targeted hybrid capture at known methylation sites. These are used after whole-genome library construction and bisulfite conversion to select regions for methylation sequencing and allow for more focused analysis.
As with transcriptome analysis (discussed earlier), the comparative changes in methylation between tumor and normal cell genomes are highly informative but do require a matched differentiation stage cell type of origin in the hematologic malignancies, to inform the comparison. Integration of the methylation changes identified in the tumor with coincident changes in tumor-specific gene expression can identify those methylation changes that truly affect the gene expression profile. 45 Methylation patterns are but one of the many regulatory aspects of cancer genomics that merit NGS-based comparison with normal progenitor cells. 46 Indeed, cancer genomics discovery efforts are continuing to identify alterations to histones that package DNA and make it available (or not) for transcription. As with methylation, DNA accessibility data can be correlated to transcriptional activity, as can the presence or absence of bound transcription factors. Although methylome studies are possible with the DNA isolated from banked tissues and blood samples, many of the aforementioned methods require cell lines or nontransformed cells growing actively in culture (when possible) to provide the input quantities of DNA required for the assays or to perform the preparatory steps required to isolate protein-bound DNA. Examples of different methods for studying general DNA accessibility include: (1) genome-wide assays of DNase I hypersensitivity to map chromatin accessibility, which provides an unbiased general characterization of open chromatin 47 ; (2) formaldehyde treatment to produce DNA-protein crosslinks in nucleosome-bound chromatin regions, followed by isolation of noncrosslinked ("open chromatin") DNA for sequencing (FAIRE-seq) 48 ; and (3) ATAC-seq, a transposase-based method that directly inserts sequencing adaptors for NGS into native chromatin. 49 More specific isolation of protein-bound DNA may be achieved by the combination of chromatin immunoprecipitation (ChIP) and high-throughput sequencing (ChIP-seq). These assays require highly specific antibodies to the protein(s) of interest. Data from ChIP-seq experiments can provide insight into how, for example, mutations in epigenetic regulators affect epigenetic marks across the genome. ChIP approaches already have been informative toward understanding mechanisms of leukemogenesis in specific hematologic malignancies bearing mutations in ASXL1. In this study, ASXL1 loss-offunction mutations resulted in a marked reduction of trimethylated histone H3 lysine 27 (H3K27me3) occupancy by inhibiting polycomb repressive complex 2 recruitment to specific oncogenic target loci. 50 Assays for epigenetic marks across the genome have an uncertain future in the clinic, but they are clearly informing our understanding of AML biology.
CONCLUSIONS
The development of methods to sequence genomes, transcriptomes, and epigenomes, either in their entirety or in part, coupled with advanced analytical and integration approaches, has transformed our understanding of the genomic origins of leukemia. Although much remains to be learned about basic discovery genomics in leukemia, efforts are also underway to introduce these approaches into clinical care of leukemia patients, ultimately affecting their therapeutic options and disease outcomes. This article has presented basic concepts regarding the underlying molecular biology of general sequencing approaches for studying DNA, RNA and epigenetics. Equally important and challenging are the analytical approaches required to make sense of the sequencing data emerging from these massively parallel instruments and to integrate across data types to construct a more nuanced understanding of the genomic landscape and how it shapes tumor biology.
